Comorbid personality impairment in body dysmorphic disorder

Lisa J. Cohen, Priscilla Kingston, Andrew Bell, Jee Kwon, Bonnie Aronowitz, Eric Hollander

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Personality impairment was evaluated in 17 body dysmorphic disorder (BDD) patients undergoing a treatment study of clomipramine versus desipramine. Semistructured interviews were administered using both categorical (Structured Clinical Interview for DSM [SCID II]) and dimensional (Dimensional Assessment of Personality Impairment [DAPI]) methods. Personality measures were also correlated with a range of clinical variables (severity of BDD and depressive symptoms, age, duration of illness, and response to treatment). A secondary aim of the study was to provide preliminary validation for the DAPI. Consistent with previous studies, BDD patients showed considerable personality pathology. By SCID II, patients met criteria for a mean of 2.53 personality disorder diagnoses; 87% of patients met criteria for at least 1 diagnosis and 53% for more than 1. Cluster C diagnoses were the most common. Mean scores for the DAPI were 2.63 (3 = mild impairment) to 6.41 (7 = severe impairment), averaging 5.26 (5 = moderate). With regard to the DAPI, the results provided preliminary evidence of good reliability and validity. Moreover, both personality measures were highly intercorrelated. Although SCID II diagnoses correlated with baseline depression (Hamilton Rating Scale for Depression [HRSD]) scores, there were few other significant correlations between personality and other clinical variables. Of note, however, treatment responders demonstrated less personality impairment than nonresponders. The finding that personality measures were highly intercorrelated but, on the whole, not well correlated with other clinical measures supports the distinct and dissociable nature of personality phenomena in BDD. Despite the small sample size, these results suggest that personality impairment appears to be significant factor in BDD and may even play a role in treatment response.

Original languageEnglish (US)
Pages (from-to)4-12
Number of pages9
JournalComprehensive Psychiatry
Volume41
Issue number1
StatePublished - Jan 2000
Externally publishedYes

Fingerprint

Body Dysmorphic Disorders
Personality
Personality Assessment
Depression
Interviews
Clomipramine
Desipramine
Personality Disorders
Therapeutics
Reproducibility of Results
Diagnostic and Statistical Manual of Mental Disorders
Sample Size
Pathology

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Biological Psychiatry
  • Psychology(all)

Cite this

Cohen, L. J., Kingston, P., Bell, A., Kwon, J., Aronowitz, B., & Hollander, E. (2000). Comorbid personality impairment in body dysmorphic disorder. Comprehensive Psychiatry, 41(1), 4-12.

Comorbid personality impairment in body dysmorphic disorder. / Cohen, Lisa J.; Kingston, Priscilla; Bell, Andrew; Kwon, Jee; Aronowitz, Bonnie; Hollander, Eric.

In: Comprehensive Psychiatry, Vol. 41, No. 1, 01.2000, p. 4-12.

Research output: Contribution to journalArticle

Cohen, LJ, Kingston, P, Bell, A, Kwon, J, Aronowitz, B & Hollander, E 2000, 'Comorbid personality impairment in body dysmorphic disorder', Comprehensive Psychiatry, vol. 41, no. 1, pp. 4-12.
Cohen LJ, Kingston P, Bell A, Kwon J, Aronowitz B, Hollander E. Comorbid personality impairment in body dysmorphic disorder. Comprehensive Psychiatry. 2000 Jan;41(1):4-12.
Cohen, Lisa J. ; Kingston, Priscilla ; Bell, Andrew ; Kwon, Jee ; Aronowitz, Bonnie ; Hollander, Eric. / Comorbid personality impairment in body dysmorphic disorder. In: Comprehensive Psychiatry. 2000 ; Vol. 41, No. 1. pp. 4-12.
@article{b8bc90a8f4704dc68f38ea3786e366c9,
title = "Comorbid personality impairment in body dysmorphic disorder",
abstract = "Personality impairment was evaluated in 17 body dysmorphic disorder (BDD) patients undergoing a treatment study of clomipramine versus desipramine. Semistructured interviews were administered using both categorical (Structured Clinical Interview for DSM [SCID II]) and dimensional (Dimensional Assessment of Personality Impairment [DAPI]) methods. Personality measures were also correlated with a range of clinical variables (severity of BDD and depressive symptoms, age, duration of illness, and response to treatment). A secondary aim of the study was to provide preliminary validation for the DAPI. Consistent with previous studies, BDD patients showed considerable personality pathology. By SCID II, patients met criteria for a mean of 2.53 personality disorder diagnoses; 87{\%} of patients met criteria for at least 1 diagnosis and 53{\%} for more than 1. Cluster C diagnoses were the most common. Mean scores for the DAPI were 2.63 (3 = mild impairment) to 6.41 (7 = severe impairment), averaging 5.26 (5 = moderate). With regard to the DAPI, the results provided preliminary evidence of good reliability and validity. Moreover, both personality measures were highly intercorrelated. Although SCID II diagnoses correlated with baseline depression (Hamilton Rating Scale for Depression [HRSD]) scores, there were few other significant correlations between personality and other clinical variables. Of note, however, treatment responders demonstrated less personality impairment than nonresponders. The finding that personality measures were highly intercorrelated but, on the whole, not well correlated with other clinical measures supports the distinct and dissociable nature of personality phenomena in BDD. Despite the small sample size, these results suggest that personality impairment appears to be significant factor in BDD and may even play a role in treatment response.",
author = "Cohen, {Lisa J.} and Priscilla Kingston and Andrew Bell and Jee Kwon and Bonnie Aronowitz and Eric Hollander",
year = "2000",
month = "1",
language = "English (US)",
volume = "41",
pages = "4--12",
journal = "Comprehensive Psychiatry",
issn = "0010-440X",
publisher = "W.B. Saunders Ltd",
number = "1",

}

TY - JOUR

T1 - Comorbid personality impairment in body dysmorphic disorder

AU - Cohen, Lisa J.

AU - Kingston, Priscilla

AU - Bell, Andrew

AU - Kwon, Jee

AU - Aronowitz, Bonnie

AU - Hollander, Eric

PY - 2000/1

Y1 - 2000/1

N2 - Personality impairment was evaluated in 17 body dysmorphic disorder (BDD) patients undergoing a treatment study of clomipramine versus desipramine. Semistructured interviews were administered using both categorical (Structured Clinical Interview for DSM [SCID II]) and dimensional (Dimensional Assessment of Personality Impairment [DAPI]) methods. Personality measures were also correlated with a range of clinical variables (severity of BDD and depressive symptoms, age, duration of illness, and response to treatment). A secondary aim of the study was to provide preliminary validation for the DAPI. Consistent with previous studies, BDD patients showed considerable personality pathology. By SCID II, patients met criteria for a mean of 2.53 personality disorder diagnoses; 87% of patients met criteria for at least 1 diagnosis and 53% for more than 1. Cluster C diagnoses were the most common. Mean scores for the DAPI were 2.63 (3 = mild impairment) to 6.41 (7 = severe impairment), averaging 5.26 (5 = moderate). With regard to the DAPI, the results provided preliminary evidence of good reliability and validity. Moreover, both personality measures were highly intercorrelated. Although SCID II diagnoses correlated with baseline depression (Hamilton Rating Scale for Depression [HRSD]) scores, there were few other significant correlations between personality and other clinical variables. Of note, however, treatment responders demonstrated less personality impairment than nonresponders. The finding that personality measures were highly intercorrelated but, on the whole, not well correlated with other clinical measures supports the distinct and dissociable nature of personality phenomena in BDD. Despite the small sample size, these results suggest that personality impairment appears to be significant factor in BDD and may even play a role in treatment response.

AB - Personality impairment was evaluated in 17 body dysmorphic disorder (BDD) patients undergoing a treatment study of clomipramine versus desipramine. Semistructured interviews were administered using both categorical (Structured Clinical Interview for DSM [SCID II]) and dimensional (Dimensional Assessment of Personality Impairment [DAPI]) methods. Personality measures were also correlated with a range of clinical variables (severity of BDD and depressive symptoms, age, duration of illness, and response to treatment). A secondary aim of the study was to provide preliminary validation for the DAPI. Consistent with previous studies, BDD patients showed considerable personality pathology. By SCID II, patients met criteria for a mean of 2.53 personality disorder diagnoses; 87% of patients met criteria for at least 1 diagnosis and 53% for more than 1. Cluster C diagnoses were the most common. Mean scores for the DAPI were 2.63 (3 = mild impairment) to 6.41 (7 = severe impairment), averaging 5.26 (5 = moderate). With regard to the DAPI, the results provided preliminary evidence of good reliability and validity. Moreover, both personality measures were highly intercorrelated. Although SCID II diagnoses correlated with baseline depression (Hamilton Rating Scale for Depression [HRSD]) scores, there were few other significant correlations between personality and other clinical variables. Of note, however, treatment responders demonstrated less personality impairment than nonresponders. The finding that personality measures were highly intercorrelated but, on the whole, not well correlated with other clinical measures supports the distinct and dissociable nature of personality phenomena in BDD. Despite the small sample size, these results suggest that personality impairment appears to be significant factor in BDD and may even play a role in treatment response.

UR - http://www.scopus.com/inward/record.url?scp=0033976865&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033976865&partnerID=8YFLogxK

M3 - Article

C2 - 10646612

AN - SCOPUS:0033976865

VL - 41

SP - 4

EP - 12

JO - Comprehensive Psychiatry

JF - Comprehensive Psychiatry

SN - 0010-440X

IS - 1

ER -